{"id":"NCT01358877","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","officialTitle":"A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-08","primaryCompletion":"2016-12-19","completion":"2024-11-28","firstPosted":"2011-05-24","resultsPosted":"2018-01-05","lastUpdate":"2025-07-24"},"enrollment":4804,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"5-Fluorouracil","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Epirubicin","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Pertuzumab","otherNames":["Perjeta®"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Trastuzumab","otherNames":["Herceptin®"]}],"arms":[{"label":"Pertuzumab + Trastuzumab + Chemotherapy","type":"EXPERIMENTAL"},{"label":"Placebo + Trastuzumab + Chemotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).","primaryOutcome":{"measure":"Percentage of Participants With Invasive Disease-Free Survival (IDFS) Event (Excluding Second Primary Non-Breast Cancer [SPNBC]), as Assessed Using Radiologic, Histologic Examinations or Laboratory Findings","timeFrame":"Randomization to the first occurrence of IDFS event (excluding SPNBC) (until data cut-off date 19 December 2016, up to maximum length of follow-up of 59 months)","effectByArm":[{"arm":"Pertuzumab + Trastuzumab + Chemotherapy","deltaMin":7.1,"sd":null},{"arm":"Placebo + Trastuzumab + Chemotherapy","deltaMin":8.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0446"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":12},"locations":{"siteCount":546,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Denmark","El Salvador","France","Germany","Guatemala","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","New Zealand","Panama","Peru","Philippines","Poland","Romania","Russia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["39259927","36681013","35313167","33828257","33539215","31924513","31305270","30976844","28581356"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":692,"n":2364},"commonTop":["Nausea","Alopecia","Diarrhoea","Fatigue","Vomiting"]}}